Sana signals progress on gene-modified islet and in vivo CAR T programs
TradingView News says Sana is progressing toward a one-time gene-modified islet therapy for type 1 diabetes, with IND filing and phase I/II trials expected soon. In vivo CAR T programs are also advancing, focused on safety and scalability.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.